| __timestamp | Genmab A/S | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 505679000 | 94231000 |
| Thursday, January 1, 2015 | 487656000 | 146394000 |
| Friday, January 1, 2016 | 660876000 | 188272000 |
| Sunday, January 1, 2017 | 874278000 | 166707000 |
| Monday, January 1, 2018 | 1431159000 | 401843000 |
| Tuesday, January 1, 2019 | 2386000000 | 560909000 |
| Wednesday, January 1, 2020 | 3137000000 | 722343000 |
| Friday, January 1, 2021 | 4181000000 | 771182000 |
| Saturday, January 1, 2022 | 5562000000 | 877090000 |
| Sunday, January 1, 2023 | 7630000000 | 877387000 |
In pursuit of knowledge
In the competitive world of biotechnology, innovation is key. Over the past decade, Genmab A/S and Sarepta Therapeutics, Inc. have been at the forefront, investing heavily in research and development (R&D). From 2014 to 2023, Genmab A/S has consistently outpaced Sarepta in R&D spending, with a staggering 1,400% increase, reaching a peak in 2023. In contrast, Sarepta's R&D expenses grew by approximately 830% over the same period. This significant investment by Genmab underscores its commitment to pioneering advancements in the biotech sector. The data reveals a clear trend: Genmab A/S is leading the charge in innovation, potentially setting the stage for groundbreaking developments in the years to come. As the biotech landscape evolves, these investments could translate into transformative therapies and substantial market advantages.
Comparing Innovation Spending: Sanofi and Sarepta Therapeutics, Inc.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Genmab A/S
R&D Insights: How Zoetis Inc. and Sarepta Therapeutics, Inc. Allocate Funds
Biogen Inc. or Genmab A/S: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Genmab A/S and Insmed Incorporated
Revenue Insights: Genmab A/S and Sarepta Therapeutics, Inc. Performance Compared
Research and Development Expenses Breakdown: Genmab A/S vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Genmab A/S vs MorphoSys AG
R&D Spending Showdown: Genmab A/S vs Ligand Pharmaceuticals Incorporated
Research and Development: Comparing Key Metrics for Genmab A/S and Wave Life Sciences Ltd.
Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs CymaBay Therapeutics, Inc.